Conference
3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
Authors
Hellmann MD; Rizvi N; Gettinger SN; Goldman J; Chow LQ; Juergens R; Borghaei H; Brahmer J; Shen Y; Harbison CT
Volume
51
Pagination
pp. s632-s633
Publisher
Elsevier
Publication Date
9 2015
DOI
10.1016/s0959-8049(16)31738-5
Conference proceedings
European Journal of Cancer
ISSN
0959-8049